中晚期非小细胞癌类型患者新辅助治疗的研究现状

Current Status of Research on Neoadjuvant Therapy for Patients with Intermediate to Advanced Non-Small Cell Cancer Types

肺部癌症目前是全球范围内发病率和死亡率极高的恶性肿瘤疾病类型之一。很多病人确诊肺癌时已经是晚期阶段,癌症已经转移其他部位,手术最佳时机已经错过。针对肺部中晚期非小细胞肺癌患者,当前指南、共识均建议采用多模式联合治疗,其中包括手术、放化疗、靶向治疗及免疫治疗等。本研究针对现在医院中晚期非小细胞肺癌新辅助治疗研究现状进行综述。肺癌是恶性肿瘤死亡的重要原因之一,非小细胞肺癌是肺部癌症的常见类型,所占比较高。早期肺癌仍以手术为主要治疗方式,但大多数患者在就诊时已发展至晚期,从而错过最佳手术机会,只能通过放疗、化疗、免疫、靶向等方法进行治疗。本文主要综述了可手术切除的局部进展期非小细胞肺癌患者新辅助治疗进展,以提高临床医生对肺癌新辅助治疗的认识。

Lung cancer is now one of the malignant tumor disease types with extremely high morbidity and mortality rates worldwide. Many patients are already in advanced stages when lung cancer is diag-nosed, and the cancer has metastasized to other sites, and the best time for surgery has been missed. For patients with mid- to late-stage non-small cell lung cancer in the lung, current guide-lines and consensus recommend multimodal combination therapy, which includes surgery, radio-therapy, targeted therapy and immunotherapy. This study reviews the current status of neoadju-vant therapy research for intermediate and advanced non-small cell lung cancer in hospitals. Lung cancer is one of the important causes of death from malignant tumors, and non-small cell lung can-cer is a common type of lung cancer, accounting for a relatively high percentage. Early stage lung cancer is still mainly treated by hand, but most patients have developed to advanced stage by the time they are diagnosed, thus missing the best surgical opportunity and can only be treated by ra-diotherapy, chemotherapy, immunotherapy, and targeted therapies. This article mainly reviews the progress of neoadjuvant treatment for patients with surgically resectable locally progressive non-small cell lung cancer to improve clinicians’ understanding of neoadjuvant treatment for lung cancer.